Jeremy Goldberg

Jeremy Goldberg


New York Office

(609) 937-2709


Jeremy joined Torreya Partners in 2008 with over 25 years of experience in the pharmaceutical industry, mainly focused on investing and business development. At Torreya, Jeremy is a member of the Biotech and Generics Advisory team, where he is active in providing transaction advice and maintaining venture capital relationships. Previously, Jeremy served as Managing Director, Corporate Development at Endo Pharmaceuticals from 2003 and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions such as the acquisitions of companies, products and product lines. Before Endo, Jeremy was a founding partner of ProQuest Investments from 1997-2002, the first cancer-focused venture capital fund. Representative investments include Conforma Therapeutics (acquired by Biogen Idec), Threshold Pharmaceuticals, and Pharmion (acquired by Celgene). Earlier in his career, Jeremy built substantial operating experience serving as founding President or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer for $1.9 billion. He has also held operating positions at SmithKline (now Glaxo SmithKline) and Becton Dickinson.

Mr. Goldberg is a magna cum laude graduate of Harvard College and Harvard Business School. He has served on Visiting Committees at Dana Farber Cancer Institute since 1999, and on the board of the International Research Alliance, a private sector philanthropy supporting NIH and Oxford and Cambridge University, since 2005, as well as on the board of private companies BioAgilityx Labs and Dominion Diagnostics and previously Cell Signaling Technology. He has been an invited speaker at the University of Pennsylvania Wharton/Windhover program for Pharmaceutical executives, Harvard Business School, and served as moderator for over 10 years for Communitech’s Cancer Progress conference.